Polaris Phase III interim analysis of lung mesothelioma study showed a chance of greater than 80% for success at the end of study

Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%.  The independent Committee conducted the interim analysis recommended that the Phase III clinical trial continue according to the protocol, without the need to increase sample size.